Efficacy and Safety of Tildrakizumab in Scalp Psoriasis

Phase 3, randomised, double-blind trial in psoriasis comparing Tildrakizumab with Placebo (2 arms). Primary endpoints: Proportion of Subjects With Investigator Global Assessment Mod 2011 (Scalp) Score of 'Clear' and 'Almost Clear' With at Least 2-point Reduction From Baseline at 16 weeks, Percentage of Subjects With Incidence, Seriousness and Severity of All Adverse Events at 72 weeks and 7 more. Started Mar 2019; status: completed.